Multivalent vaccines for hand-foot-mouth disease, their preparation methods and applications

By developing a multivalent vaccine containing multiple viral strains, the problem that existing vaccines cannot effectively prevent hand-foot-mouth disease caused by multiple enteroviruses has been solved, achieving the effects of broad-spectrum prevention and simplified vaccination procedures.

CN116350766BActive Publication Date: 2026-11-17SINOVAC BIOTECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202111621058.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-12-27
Publication Date
2026-11-17
Estimated Expiration
2041-12-27

AI Technical Summary

Technical Problem

Current vaccines are not effective in preventing hand, foot, and mouth disease caused by a variety of enteroviruses, especially strains other than EV71 and CA16, making it difficult to control outbreaks and epidemics of HFMD.

Method used

A multivalent vaccine was developed, comprising inactivated CA4, CA24, CB4, Echo6, EV71, CA16, CA10, and CA6 viral strains. The viral fluid was purified by physical methods through adsorption and mixing with aluminum adjuvant to ensure safety and stability.

Benefits of technology

It achieves broad-spectrum prevention against multiple viral strains, simplifies the vaccination procedure, improves vaccination efficiency, reduces costs, and maintains good immunogenicity and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003437456860000081
    Figure BDA0003437456860000081
  • Figure BDA0003437456860000091
    Figure BDA0003437456860000091
  • Figure BDA0003437456860000092
    Figure BDA0003437456860000092
Patent Text Reader

Abstract

This invention discloses a vaccine for the prevention or treatment of hand-foot-mouth disease, comprising inactivated Coxsackievirus A4, Coxsackievirus A24, Coxsackievirus B4, and / or Echovirus 6. The vaccine may also comprise Enterovirus 71, Coxsackievirus A16, Coxsackievirus A10, and / or Coxsackievirus A6. This invention also discloses a method for preparing the vaccine and its applications.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology, specifically relating to a vaccine for the prevention or treatment of hand-foot-mouth disease, its preparation method, and its application. Background Technology

[0002] Hand-foot-mouth disease (HFMD) is an acute infectious disease caused by various enteroviruses, and it is more common in infants and young children. The main symptoms of HFMD are rashes on the mouth, hands, and feet, and it can lead to severe complications such as meningitis, encephalitis, pulmonary edema, and circulatory failure, which can result in death.

[0003] Besides enterovirus 71 (EV71) and Coxsackievirus A16 (CA16), which are relatively common viruses that cause hand-foot-mouth disease (HFMD), other common causes include Coxsackievirus A (CA) types 2, 4, 5, 6, 10, and 24; Coxsackievirus B (CB) types 1, 2, 3, 4, and 5; enterovirus 68 (EV68); and echovirus (Echo) types 6, 25, and 30. EV71 and CA16 are the main pathogens causing HFMD outbreaks. In recent years, reports of HFMD outbreaks caused by CA10, CA24, and CA6 have gradually increased, and in some areas they have even become the main circulating serotypes.

[0004] Hand, foot, and mouth disease (HFMD) has become a serious public health problem threatening children's health and social stability. Currently, there are no effective antiviral drugs for treating HFMD. Although an approved EV71 inactivated vaccine is available, changes in the enterovirus spectrum causing HFMD and the diversity of dominant strains leading to its prevalence, coupled with the lack of cross-immune protection between strains, make it impossible to protect against infections with other types of HFMD, posing new challenges to HFMD control. Furthermore, EV71 inactivated vaccines are insufficient to control outbreaks and epidemics of HFMD caused by CA16, CA10, CA6, and Echo strains.

[0005] Therefore, there is an urgent need for a multi-serotype vaccine that can prevent hand-foot-mouth disease on a wider scale in order to cope with the outbreak and epidemic of severe HFMD. Summary of the Invention

[0006] To address the aforementioned problems, this invention screened novel viral strains with good immunogenicity that can be used to prevent, treat, or combat hand-foot-mouth disease. Based on this, vaccines or agents for the prevention or treatment of hand-foot-mouth disease were developed.

[0007] According to one aspect of the present invention, a vaccine for the prevention or treatment of hand-foot-mouth disease is provided, said vaccine comprising inactivated Coxsackievirus A4 (CA4) strain, inactivated Coxsackievirus A24 (CA24) strain, inactivated Coxsackievirus B4 (CB4) strain and / or inactivated Echovirus 6 (Echo6) strain.

[0008] According to some embodiments of the present invention, the Coxsackievirus A4 (CA4) strain was deposited on December 2, 2021, at the China General Microbiological Culture Collection Center (CGMCC) (No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing), with accession number CGMCC NO:45051.

[0009] According to some embodiments of the present invention, the Coxsackievirus A24 (CA24) strain was deposited on December 2, 2021, at the China General Microbiological Culture Collection Center (CGMCC) (No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing), with accession number CGMCC NO:45052.

[0010] According to some embodiments of the present invention, the Coxsackievirus Group B4 (CB4) strain was deposited on December 2, 2021, at the China General Microbiological Culture Collection Center (CGMCC) (No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing), with accession number CGMCC NO:45053.

[0011] According to some embodiments of the present invention, the Echovirus 6 strain was deposited on December 2, 2021, at the China General Microbiological Culture Collection Center (CGMCC) (No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing), with accession number CGMCC NO:45054.

[0012] According to some embodiments of the present invention, the vaccine further includes inactivated enterovirus 71 (EV71), inactivated Coxsackievirus A16 (CA16), inactivated Coxsackievirus A10 (CA10), and / or inactivated Coxsackievirus A6 (CA6). According to some embodiments of the present invention, the vaccine includes inactivated CA4, CA24, CB4, Echo6, EV71, CA16, CA10, and CA6.

[0013] According to some embodiments of the present invention, the enterovirus 71 (EV71) strain is deposited under CGMCC No. 3544. According to some embodiments of the present invention, the Coxsackievirus A16 (CA16) strain is deposited under CGMCC NO: 18886. According to some embodiments of the present invention, the Coxsackievirus A10 (CA10) strain is deposited under CGMCC NO: 18887. According to some embodiments of the present invention, the Coxsackievirus A6 (CA6) strain is deposited under CGMCC NO: 18888.

[0014] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated enterovirus 71 is 100-1000 U / mL, preferably 500-1000 U / mL.

[0015] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated Coxsackievirus A16 is 200-3000 U / mL, preferably 200-1600 U / mL, and more preferably 800-1200 U / mL.

[0016] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated Coxsackievirus A10 is 200-3000 U / mL, preferably 200-1600 U / mL, and more preferably 800-1200 U / mL.

[0017] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated Coxsackievirus A6 group is 1000-3000 U / mL, preferably 1500-3000 U / mL, and more preferably 1600-2400 U / mL.

[0018] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated Coxsackievirus A4 type is 200-3000 U / mL, preferably 1000-3000 U / mL, and more preferably 1600-2400 U / mL.

[0019] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated Coxsackievirus A24 is 200-3000 U / mL, preferably 1000-3000 U / mL, and more preferably 1600-2400 U / mL.

[0020] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated Coxsackievirus B4 group is 200-3000 U / mL, preferably 1000-3000 U / mL, and more preferably 1600-2400 U / mL.

[0021] According to some embodiments of the present invention, in the vaccine, the antigen content of the inactivated echovirus type 6 is 200-3000 U / mL, preferably 1000-3000 U / mL, and more preferably 1600-2400 U / mL.

[0022] According to a specific embodiment of the present invention, the vaccine further includes an aluminum adjuvant. According to one specific embodiment of the present invention, the aluminum adjuvant is selected from aluminum hydroxide, aluminum phosphate, or aluminum sulfate. According to a specific embodiment of the present invention, the final concentration of aluminum content in the aluminum adjuvant, calculated as aluminum ions, is 0.1–1.0 mg / mL, preferably 0.2–0.8 mg / mL.

[0023] According to some embodiments of the present invention, the vaccine is a liquid dosage form.

[0024] According to another aspect of the present invention, a method for preparing the vaccine is also provided. According to some embodiments of the present invention, the method includes the following steps: preparing inactivated CA4, CA24, CB4, Echo6, EV71, CA16, CA10 and / or CA6 viral stock solutions respectively; adsorbing the stock solutions onto aluminum adjuvants respectively to prepare viral aluminum adsorption products; and then mixing the aluminum adsorption products to prepare the vaccine.

[0025] According to a specific embodiment of the present invention, a purified vaccine virus solution can be prepared by the following steps:

[0026] (1) Inactivate CA4, CA24, CB4, Echo6, EV71, CA16, CA10 and / or CA6 viruses respectively, and concentrate them by ultrafiltration;

[0027] (2) The concentrated CA4, CA24, CB4, Echo6, EV71, CA16, CA10 and / or CA6 virus solutions after ultrafiltration were subjected to sucrose density gradient centrifugation.

[0028] (3) Collect the centrifuged liquid and combine it.

[0029] According to specific embodiments of the present invention, viral purification solutions of CA4, CA24, CB4, Echo6, EV71, CA16, CA10 and / or CA6 can be prepared in advance.

[0030] According to a specific embodiment of the present invention, EV71 stock solution can be prepared by the following steps: EV71 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a microcarrier fermenter for scale-up or in a cell factory for 5-9 days; the viral fluid is harvested; the viral fluid is inactivated by formaldehyde; ultrafiltration is performed using a 100-500 kDa ultrafiltration membrane for concentration; the ultrafiltration-concentrated viral fluid is purified by sucrose density gradient centrifugation; the collected target viral fluids are combined and desaccharified by ultrafiltration; the desaccharified viral fluid is treated with a non-restriction endonuclease; host cell DNA is removed by ultrafiltration; and molecular sieve chromatography is used to remove impurities such as endonucleases to obtain EV71 virus stock solution.

[0031] According to a specific embodiment of the present invention, CA16 stock solution can be prepared by the following steps: CA16 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory plane for 4-9 days; the virus solution is harvested; the virus solution is clarified and concentrated by ultrafiltration using a 100-500 kDa ultrafiltration membrane; the concentrated virus solution is centrifuged using a sucrose density gradient to remove impurities; the collected target virus solutions are combined and desaccharified by ultrafiltration; the desaccharified virus solution is treated with a non-restriction endonuclease; host cell DNA is removed by ultrafiltration; molecular sieve chromatography is used to remove endonuclease and other impurities; and formaldehyde is used for inactivation to obtain CA16 virus stock solution.

[0032] According to a specific embodiment of the present invention, CA10 stock solution can be prepared by the following steps: CA10 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory plane for 2-9 days; the virus solution is harvested; the virus solution is clarified and concentrated by ultrafiltration using a 100-500 kDa ultrafiltration membrane; the concentrated virus solution is centrifuged using a sucrose density gradient to remove impurities; the collected target virus solutions are combined and desaccharified by ultrafiltration; the desaccharified virus solution is treated with a non-restriction endonuclease and ultrafiltration is used to remove host cell DNA; molecular sieve chromatography is used to remove endonuclease and other impurities; and formaldehyde is used for inactivation to obtain CA10 virus stock solution.

[0033] According to a specific embodiment of the present invention, CA6 stock solution can be prepared by the following steps: CA6 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory plane for 3-9 days; the viral fluid is harvested; the viral fluid is clarified and concentrated by ultrafiltration using a 100-500 kDa ultrafiltration membrane; the concentrated viral fluid is centrifuged using a sucrose density gradient to remove impurities; the collected target viral fluids are combined and desaccharified by ultrafiltration; the desaccharified viral fluid is treated with a non-restriction endonuclease and ultrafiltration is used to remove host cell DNA; molecular sieve chromatography is used to remove endonuclease and other impurities; and formaldehyde is used for inactivation to obtain CA6 virus stock solution.

[0034] According to a specific embodiment of the present invention, CA4 stock solution can be prepared by the following steps: CA4 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory plane for 2-9 days; the viral fluid is harvested; the viral fluid is clarified and concentrated by ultrafiltration using a 100-500 kDa ultrafiltration membrane; the concentrated viral fluid is purified by sucrose density gradient centrifugation to remove impurities; the collected target viral fluids are combined and desaccharified by ultrafiltration; the desaccharified viral fluid is treated with a non-restriction endonuclease and ultrafiltration is used to remove host cell DNA; molecular sieve chromatography is used to remove residual endonucleases and other impurities; and formaldehyde is used for inactivation to obtain CA4 virus stock solution.

[0035] According to a specific embodiment of the present invention, CA24 stock solution can be prepared by the following steps: CA24 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory plane for 3-9 days; the viral fluid is harvested; the viral fluid is clarified and concentrated by ultrafiltration using a 100-500 kDa ultrafiltration membrane; the concentrated viral fluid is purified by sucrose density gradient centrifugation to remove impurities; the collected target viral fluids are combined and desaccharified by ultrafiltration; the desaccharified viral fluid is treated with a non-restriction endonuclease and ultrafiltration is used to remove host cell DNA; molecular sieve chromatography is used to remove residual endonuclease and other impurities; and formaldehyde is used for inactivation to obtain CA24 virus stock solution.

[0036] According to a specific embodiment of the present invention, CB4 stock solution can be prepared by the following steps: CB4 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory plane for 2-9 days; the viral fluid is harvested; the viral fluid is clarified and concentrated using a 100-500 kDa ultrafiltration membrane; the concentrated viral fluid is purified by sucrose density gradient centrifugation to remove impurities; the collected target viral fluids are combined and desaccharified by ultrafiltration; the desaccharified viral fluid is treated with a non-restriction endonuclease and ultrafiltration is used to remove host cell DNA; molecular sieve chromatography is used to remove residual endonucleases and other impurities; and formaldehyde is used for inactivation to obtain CB4 virus stock solution.

[0037] According to a specific embodiment of the present invention, Echo6 stock solution can be prepared by the following steps: Echo6 virus is inoculated into Vero cells at a certain MOI (multiple of infection), and cultured in a fermenter microcarrier for stepwise scale-up or in a cell factory for 2-9 days; the viral fluid is harvested; the viral fluid is clarified and concentrated by ultrafiltration using a 100-500 kDa ultrafiltration membrane; the concentrated viral fluid is purified by sucrose density gradient centrifugation to remove impurities; the collected target viral fluids are combined and desaccharified by ultrafiltration; the desaccharified viral fluid is treated with a non-restriction endonuclease and ultrafiltration is used to remove host cell DNA; molecular sieve chromatography is used to remove residual endonucleases and other impurities; and formaldehyde is used for inactivation to obtain Echo6 virus stock solution.

[0038] The virus purification process is carried out entirely using physical methods, which effectively removes impurities such as host proteins, host DNA, and endonucleases, thus ensuring vaccine safety.

[0039] The stock solutions of the five serotypes were adsorbed with aluminum adjuvants and then mixed in a certain proportion to prepare a vaccine semi-finished product, which was then packaged into a finished vaccine.

[0040] According to another aspect of the present invention, the use of the vaccine of the present invention in the prevention or treatment of hand-foot-mouth disease is provided.

[0041] The term "hand, foot, and mouth disease" or "HFMD" as used in this article refers to an acute infectious disease caused by various enteroviruses. Viruses that cause HFMD include enteroviruses (EVs) and Coxsackieviruses, with EV71 and CA16 being the most common. In addition, Coxsackieviruses include Coxsackievirus A (CA) types 2, 4, 5, 6, 10, and 24; Coxsackievirus B (CB) types 1, 2, 3, 4, and 5; enterovirus 68 (EV68); and echoviruses 6, 25, and 30.

[0042] According to a specific embodiment of the present invention, the vaccine can prevent or treat hand-foot-mouth disease caused by CA4, CA24, CB4, Echo6, EV71, CA16, CA10 and / or CA6. In addition to hand-foot-mouth disease caused by the aforementioned viruses, the vaccine of the present invention can also prevent or treat hand-foot-mouth disease caused by other enteroviruses on a broader scale.

[0043] The term "cytopathic effect" or "CPE" used in this article refers to the phenomenon observed under a microscope in in vitro experiments after cell culture and inoculation with cell-killing viruses, characterized by cell rounding, necrosis, and detachment from the flask wall. Characteristic enterovirus-induced cytopathic effects typically manifest as cell rounding, increased refractive index, and detachment from the flask wall.

[0044] Currently, there are no reports on the development of multivalent vaccines combining CA4, CA24, CB4, Echo6, EV71, CA16, CA10, and / or CA6. This invention provides, for the first time, a multivalent vaccine combining CA4, CA24, CB4, Echo6, EV71, CA16, CA10, and / or CA6, particularly an octavalent vaccine combining CA4, CA24, CB4, Echo6, EV71, CA16, CA10, and CA6, which effectively prevents hand-foot-mouth disease caused by CA4, CA24, CB4, Echo6, EV71, CA16, CA10, and / or CA6 viruses. Studies show that the vaccine of this invention can simultaneously prevent infection by multiple pathogens, and there is no interference between these antigens. The corresponding immunogenicity is not reduced compared to the immunogenicity induced by single antigens, exhibiting excellent immunogenicity and safety, good stability, and long-term storage. The use of multivalent vaccines can significantly simplify the vaccination procedure, improve vaccination efficiency, and reduce costs. The vaccine manufacturing process of this invention exhibits good consistency and stability. Through extensive experimentation, the optimal inactivation process parameters have been selected, which not only improves the safety performance of the vaccine and achieves complete inactivation, but also minimizes the amount of formaldehyde used, thus saving costs. Detailed Implementation

[0045] The present invention will be further illustrated below by way of embodiments. It should be understood that these embodiments of the present invention are merely exemplary descriptions of the present invention and should not be construed as limiting the present invention.

[0046] Example 1. Isolation of the virus strain

[0047] Throat swabs or feces from patients with hand-foot-mouth disease were obtained from disease control and prevention centers in multiple locations. The samples were diluted with physiological saline, centrifuged, and filtered through 0.45μm and 0.22μm filters for sterilization. Sensitive cells (Vero cells or human diploid cells) with good growth and confluence into a monolayer were selected. The virus culture medium was M199 medium (GIBCO) containing 2% fetal bovine serum. The treated throat swabs / feces samples were inoculated at a specific ratio and incubated statically at 32.0℃–36.5℃ in a 5% CO2 incubator. The cells were observed daily for the presence of characteristic enterovirus-induced cytopathic effect (CPE). If CPE was observed and the CPE level reached +++ (1+, <25%; 2+, 25%–50%; 3+, 50%–75%; 4+, 75%–100%) or higher, the cell culture was harvested and passaged twice more. If no CPE occurs, culture until day 7, freeze-thaw once, harvest the cell culture, and passage the cell culture twice more. Use one well-grown cell culture tube that has not been inoculated as a cell control. If no CPE occurs in the cell control, the experiment is successful.

[0048] After three blind passages, the cell culture specimens showing CPE were judged to be positive for virus isolation, and the cell cultures that were positive for virus isolation were further identified by PCR.

[0049] Example 2. Identification of the strain

[0050] The strains isolated in Example 1 were identified at the immunological and molecular levels using ELISA and PCR, respectively.

[0051] (1) Identification by ELISA

[0052] EV71 antigen detection system: Coat with EV71 rabbit polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum (Lanzhou Minhai) at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash the plate 3-5 times, add EV71 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash the plate 3-5 times, develop color, and terminate the reaction.

[0053] CA16 antigen detection system: Coat with CA16 rabbit polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash 3-5 times, add CA16 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash 3-5 times, develop color, and terminate the reaction.

[0054] CA10 antigen detection system: Coat with CA10 rabbit polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash the plate 3-5 times, add CA10 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash the plate 3-5 times, develop color, and terminate the reaction.

[0055] CA6 antigen detection system: Coat with CA6 polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash 3-5 times, add CA6 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash 3-5 times, develop color, and terminate the reaction.

[0056] CA4 antigen detection system: Coat with CA4 polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash 3-5 times, add CA4 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash 3-5 times, develop color, and terminate the reaction.

[0057] CA24 antigen detection system: Coat with CA24 rabbit polyclonal antibody (Beijing Sinovac) overnight at 2-8℃, block with 10% fetal bovine serum at 37℃ for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37℃ for 1 hour, wash the plate 3-5 times, add CA24 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37℃ for 1 hour, wash the plate 3-5 times, develop color, and terminate the reaction.

[0058] CB4 antigen detection system: Coat with CB4 polyclonal antibody (Beijing Sinovac) overnight at 2-8°C, block with 10% fetal bovine serum at 37°C for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37°C for 1 hour, wash 3-5 times, add CB4 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37°C for 1 hour, wash 3-5 times, develop color, and terminate the reaction.

[0059] Echo6 antigen detection system: Coat with Echo6 polyclonal antibody (Beijing Sinovac) overnight at 2-8°C, block with 10% fetal bovine serum at 37°C for 1-2 hours, add the virus culture to be identified, set up negative control wells, incubate at 36-37°C for 1 hour, wash 3-5 times, add Echo6 type-specific monoclonal antibody (Beijing Sinovac), incubate at 36-37°C for 1 hour, wash 3-5 times, develop color, and terminate the reaction.

[0060] The strains isolated in Example 1, as well as the CA16, CA10, CA6, and EV71 strains used, were identified using the eight antigen detection systems described above. The results are shown in Tables 1 to 8.

[0061] Table 1. Results of ELISA antigen identification of CA16 strain

[0062] Antigen detection system OD value Result judgment EV71 virus 0.049 Negative CA16 virus 2.015 Positive CA10 virus 0.054 Negative CA6 virus 0.061 Negative Echo6 virus 0.052 Negative CA24 virus 0.046 Negative CA4 virus 0.058 Negative CB4 virus 0.048 Negative Negative control well 0.068 negative results

[0063] Table 2. Results of ELISA antigen system identification of CA10 strain

[0064] Antigen detection system OD value Result judgment EV71 strain 0.056 Negative CA16 strain 0.034 Negative CA10 strain 1.875 Positive CA6 strain 0.049 Negative Echo6 strain 0.056 Negative CA24 strain 0.066 Negative CA4 strain 0.052 Negative CB4 strain 0.060 Negative Negative control well 0.058 negative results

[0065] Table 3. Results of ELISA antigen system identification of CA6 strain

[0066]

[0067]

[0068] Table 4. Results of ELISA antigen identification of Echo6 strain

[0069] Antigen detection system OD value Result judgment EV71 strain 0.062 Negative CA16 strain 0.040 Negative CA10 strain 0.057 Negative CA6 strain 0.045 Negative Echo6 strain 1.966 Positive CA24 strain 0.052 Negative CA4 strain 0.049 Negative CB4 strain 0.055 Negative Negative control well 0.050 negative results

[0070] Table 5. Results of ELISA antigen identification of CA24 strain

[0071] Antigen detection system OD value Result judgment EV71 strain 0.058 Negative CA16 strain 0.038 Negative CA10 strain 0.061 Negative CA6 strain 0.055 Negative Echo6 strain 0.043 Negative CA24 strain 2.136 Positive CA4 strain 0.050 Negative CB4 strain 0.048 Negative Negative control well 0.062 negative results

[0072] Table 6. Results of ELISA antigen identification of CA4 strain

[0073]

[0074]

[0075] Table 7. Results of ELISA antigen system identification of CB4 strain +

[0076] Antigen detection system OD value Result judgment EV71 strain 0.052 Negative CA16 strain 0.044 Negative CA10 strain 0.059 Negative CA6 strain 0.048 Negative Echo6 strain 0.056 Negative CA24 strain 0.045 Negative CA4 strain 0.064 Negative CB4 strain 1.985 Positive Negative control well 0.061 negative results

[0077] Table 8. Results of ELISA antigen identification of EV71 strain

[0078] Antigen detection system OD value Result judgment EV71 strain 2.046 Positive CA16 strain 0.039 Negative CA10 strain 0.043 Negative CA6 strain 0.038 Negative Echo6 strain 0.040 Negative CA24 strain 0.041 Negative CA4 strain 0.045 Negative CB4 strain 0.051 Negative Negative control well 0.050 negative results

[0079] (2) Identification at the molecular level

[0080] Viral RNA was extracted using an RNA extraction kit (QIAGEN), and the extracted RNA was subjected to one-step reverse transcription and PCR amplification using a reverse transcription kit (TAKARA). Primer sequences were designed in-house and synthesized by BGI Genomics Co., Ltd. The PCR products were identified by 1% agarose gel electrophoresis. Reverse transcription conditions:

[0081]

[0082] PCR amplification and sequencing were performed. The sequencing results were compared with the NCBI database, and the virus strains isolated in Example 1 were identified as the corresponding types CA4, CA24, CB4, and Echo6 strains. Seed banks of these strains were established and deposited at the China General Microbiological Culture Collection Center (CGMCC). The accession number for CA4 strain is CGMCC NO:45051; for CA24 strain, it is CGMCC NO:45052; for CB4 strain, it is CGMCC NO:45053; and for Echo6 strain, it is CGMCC NO:45054.

[0083] Example 3. Production of a single-component stock solution

[0084] The dosage of microcarriers (GE Healthcare, Cytodex) in a 130L fermenter is 2–6 g / L, based on a cell count of 10–50 × 10⁻⁶. 4 Inoculate Vero cells at a concentration of 10 cells / mL, pH 7.0–7.5, dissolved oxygen level approximately 50%, and culture at 35–37.5°C for 3–7 days. Based on the cell count, inoculate with virus at a ratio of MOI 0.001–0.1, continue culturing for 3–6 days, and harvest the virus-containing culture supernatant.

[0085] The supernatant was clarified and concentrated using an ultrafiltration membrane with a membrane density of 100–500 kDa to remove impurities and proteins. The concentrated virus solution was then purified by sucrose density gradient centrifugation to remove impurities and separate solid and hollow virus particles. Centrifugation conditions were 2–8 °C, 20,000–50,000 rpm, and 8–18 hours. The target viruses were collected and ultrafiltered for desaccharification. Non-restriction endonucleases were used to treat the desaccharified virus solution with stirring at 18–30 °C. Then, host cell DNA was removed by ultrafiltration, and residual endonucleases and other impurities were removed by molecular sieve chromatography. The virus was inactivated using a 1:2000–1:8000 formaldehyde solution at 35–38 °C for 2–6 days until completely inactivated. These steps yielded inactivated stock solutions of CA6, CA16, CA10, CA4, CA24, CB4, and Echo6 strains.

[0086] The production of EV71 stock solution is carried out by fermentation tank or cell factory culture. After the virus is harvested, it is first inactivated and then purified. Other process steps are comparable to those of CA6, CA16, CA10, CA4, CA24, CB4 and Echo6 strains.

[0087] Example 4. Preparation of monovalent aluminum adsorbed vaccine

[0088] Preparation of monovalent aluminum-adsorbed vaccines: Aluminum adjuvant was diluted to 3.0 mg / mL (calculated as Al(OH)3) with 0.85% physiological saline. EV71 antigen was diluted to 400-6000 U / mL with 0.01 M PBS. CA16 and CA10 antigens were diluted to 800-9600 U / mL. CA6 antigen was diluted to 4000-18000 U / mL. CA4 antigen was diluted to 3000-18000 U / mL. CA24 antigen was diluted to 3000-18000 U / mL. CB4 antigen was diluted to 3000-18000 U / mL. Echo6 antigen was diluted to 800-15000 U / mL. At room temperature, diluted aluminum adjuvant was added to diluted EV71, CA16, CA10, CA6, CA4, CA24, CB4, and Echo6 antigens respectively, so that the two were adsorbed in equal volumes. Stirring was carried out while adding the adjuvant. After the adsorption was completed, the mixture was mixed at room temperature for 30 minutes to obtain monovalent aluminum adsorbed vaccines of EV71, CA16, CA10, CA6, CA4, CA24, CB4, and Echo6.

[0089] Example 5. Preparation of the octavalent vaccine

[0090] The above eight types of monovalent aluminum adsorption products are mixed and packaged in a certain proportion to prepare the finished eight-valent hand-foot-mouth disease vaccine. The specific operation process is as follows:

[0091] The monovalent aluminum adsorbed vaccines EV71, CA16, CA10, CA6, CA4, CA24, CB4, and Echo6 obtained above were mixed in a certain proportion. Based on the antigen content of the vaccine stock solution, they were appropriately diluted with 0.01M PBS (pH 7.2) solution and aluminum hydroxide solution. Then, the mixture was stirred and adsorbed at room temperature for 20±10 minutes to obtain the vaccine semi-finished product. In the obtained vaccine semi-finished product, the final concentration of aluminum hydroxide is approximately 1.30 mg / mL (equivalent to a final aluminum ion concentration of 0.45 mg / mL), the antigen content of EV71 is 960 U / mL, the antigen content of CA16 is 200–1600 U / mL, the antigen content of CA10 is 200–1600 U / mL, the antigen content of CA6 is 1000–3000 U / mL, the antigen content of CA4 is 1000–3000 U / mL, the antigen content of CA24 is 1000–3000 U / mL, the antigen content of CB4 is 1000–3000 U / mL, and the antigen content of Echo6 is 200–2500 U / mL. The protein dose range corresponding to the above antigen contents in the semi-finished product is 1–8 μg / mL, that is, the total protein dose of the octavalent semi-finished vaccine is 8–64 μg / mL. The obtained vaccine semi-finished product is then filled into syringes to obtain the finished vaccine. The dosage of the finished vaccine is 0.5 mL per person, and the protein content of each viral component in the finished vaccine is ≤4 μg per person.

[0092] The octavalent hand-foot-mouth disease vaccine was prepared according to the above method, and the specific parameters are shown in Table 9. Three consecutive batches of vaccine were prepared for each parameter.

[0093] Table 9. Parameter settings for the octavalent vaccine

[0094]

[0095] Example 6. Evaluation of the octavalent vaccine

[0096] (1) Testing of the finished octavalent vaccine

[0097] The aluminum hydroxide content, supernatant antigen content, and post-dissociation antigen content of the above-mentioned octavalent hand-foot-mouth disease vaccines 1-15 were detected respectively, and the adsorption rate and dissociation rate were calculated. The results are shown in Table 10.

[0098]

[0099]

[0100] (2) Immunogenicity test

[0101] Three batches of the octavalent vaccine described above were used to immunize rats and mice twice each, and the titers of neutralizing antibodies in their serum were detected. A monovalent vaccine control and a negative control were also established. The assay was repeated three times. The neutralizing antibody titer was detected using the microcytopathic effect method. Human malignant embryonic rhabdomyosarcoma (RD) cells were used for the assay; the cells were cultured at 37°C for 7 days, and cytopathic effects were observed. The results of the neutralizing antibody titers and seroconversion rates are shown in Table 11. The immunogenicity of each viral component in the vaccine was statistically analyzed compared with the corresponding monovalent vaccine, and the results are shown in Table 12. According to the statistical analysis, there was no significant difference in the geometric mean titer (GMT) of neutralizing antibodies between the octavalent and monovalent vaccines (P values ​​were all greater than 0.05).

[0102] Table 11. Neutralizing antibody titer and seroconversion rate

[0103]

[0104] Table 12. Statistical analysis of immunogenicity results between the octavalent and monovalent vaccines.

[0105]

[0106] (3) Safety evaluation

[0107] Throughout the experimental period assessing the immunogenicity of each vaccine, all animals survived healthily with no abnormal clinical manifestations. Abnormal toxicity tests were conducted on three batches of the EV71 / CA16 / CA10 / CA6 / CA4 / CA24 / CB4 / Echo6 octavalent vaccine (Vaccine 1) to verify its animal safety evaluation.

[0108] The adverse toxicity tests included mouse and guinea pig studies. In the mouse study, five mice weighing 18–22g were injected with the EV71 / CA16 / CA10 / CA6 / CA4 / CA24 / CB4 / Echo6 octavalent vaccine, 0.5 mL per mouse, and observed for 7 days. During the observation period, all mice survived without adverse reactions, and their body weight increased at the end of the observation period. In the guinea pig study, two guinea pigs weighing 250–350g were injected with the EV71 / CA16 / CA10 / CA6 / CA4 / CA24 / CB4 / Echo6 vaccine, 5 mL per guinea pig, and observed for 7 days. During the observation period, all guinea pigs survived without adverse reactions, and their body weight increased at the end of the observation period.

[0109] (4) Stability evaluation

[0110] Three batches of the combined vaccine (Vaccine 1) were stored at 2–8°C. Samples were taken at specific time points to test antigen content, appearance, dosage, pH value, osmolality, bacterial endotoxin, and formaldehyde content. Data were recorded for up to 12 months, and abnormal toxicity and immunogenicity of the vaccine were tested in the 12th month. After 12 months of storage at 2–8°C, no significant decrease was observed in any of the tested indicators. The results are shown in Tables 13–15.

[0111] Table 13. Antigen content test results of the finished octavalent vaccine after being stored at 2–8℃ for a period of time.

[0112]

[0113] Table 14. pH value, osmolar concentration and sterility test of the octavalent vaccine product after storage at 2-8℃ for a period of time.

[0114]

[0115] Table 15. Toxicity and neutralizing antibody GMT of the octavalent vaccine product after storage at 2–8°C for a period of time.

[0116]

[0117] Note: " / " indicates that this test was not performed.

[0118] In addition to vaccine 1, vaccines 2–15 also underwent immunogenicity testing, as well as safety and stability evaluations. The results showed that the neutralizing antibody GMT values ​​of vaccines 2–15 were not significantly different from those of the monovalent vaccines. Furthermore, vaccines 2–15, like vaccine 1, exhibited good safety and high stability.

[0119] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the specific details of the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solutions of the present invention, and these simple modifications all fall within the protection scope of the present invention. Furthermore, it should be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. To avoid unnecessary repetition, the present invention will not describe the various possible combinations separately. In addition, various different embodiments of the present invention can also be arbitrarily combined, as long as they do not violate the spirit of the present invention, they should also be considered as the content disclosed by the present invention.

Claims

1. A vaccine for preventing hand, foot and mouth disease, characterized in that, The vaccine comprises inactivated Coxsackievirus A4 strain, inactivated Coxsackievirus A24 strain, inactivated Coxsackievirus B4 strain, inactivated echovirus 6 strain, inactivated enterovirus 71 strain, inactivated Coxsackievirus A16 strain, inactivated Coxsackievirus A10 strain, and inactivated Coxsackievirus A6 strain. The preservation number of the Coxsackievirus Group A4 strain is CGMCC NO:45051; The preservation number of the Coxsackievirus Group A24 strain is CGMCC NO:45052; The preservation number of the Coxsackievirus Group B4 strain is CGMCC NO:45053; The preservation number of the echovirus type 6 strain is CGMCC NO:45054; The preservation number of the enterovirus type 71 strain is CGMCC No. 3544; The preservation number of the Coxsackievirus Group A16 strain is CGMCC NO:18886; The preservation number of the Coxsackievirus Group A10 strain is CGMCC NO:18887; The preservation number of the Coxsackievirus Group A6 strain is CGMCC NO:18888.

2. The vaccine of claim 1, characterized in that, In the vaccine, The content of the inactivated Coxsackievirus A4 strain is 200-3000 U / mL; The content of the inactivated Coxsackievirus A24 strain was 200–3000 U / mL; The content of the inactivated Coxsackievirus Group B4 strain is 200-3000 U / mL; The concentration of the inactivated echovirus type 6 strain was 200–3000 U / mL.

3. The vaccine of claim 2, characterized in that, In the vaccine, The concentration of the inactivated Coxsackievirus A4 strain was 1000–3000 U / mL.

4. The vaccine of claim 2, wherein, In the vaccine, The concentration of the inactivated Coxsackievirus A24 strain was 1000–3000 U / mL.

5. The vaccine according to claim 2, characterized in that, In the vaccine, The concentration of the inactivated Coxsackievirus Group B4 strain was 1000–3000 U / mL.

6. The vaccine according to claim 2, characterized in that, In the vaccine, The inactivated echovirus type 6 strain contained 1000–3000 U / mL.

7. The vaccine according to any one of claims 1 to 6, characterized in that, In the vaccine, The content of the inactivated enterovirus type 71 strain is 100-1000 U / mL; The content of the inactivated Coxsackievirus A16 strain is 200-3000 U / mL; The content of the inactivated Coxsackievirus A10 strain is 200-3000 U / mL; The concentration of the inactivated Coxsackievirus A6 strain was 1000–3000 U / mL.

8. The vaccine according to claim 7, characterized in that, In the vaccine, The concentration of the inactivated enterovirus 71 strain is 500–1000 U / mL.

9. The vaccine according to claim 7, characterized in that, In the vaccine, The concentration of the inactivated Coxsackievirus A16 strain was 200–1600 U / mL.

10. The vaccine according to claim 7, characterized in that, In the vaccine, The concentration of the inactivated Coxsackievirus A10 strain was 200–1600 U / mL.

11. The vaccine according to claim 7, characterized in that, In the vaccine, The concentration of the inactivated Coxsackievirus A6 strain was 1500–3000 U / mL.

12. The vaccine according to any one of claims 1 to 6, 8 to 11, characterized in that, The vaccine also includes an aluminum adjuvant.

13. The vaccine according to claim 12, characterized in that, The aluminum adjuvant is selected from aluminum hydroxide, aluminum phosphate, or aluminum sulfate.

14. The vaccine according to claim 13, characterized in that, The final concentration of aluminum in the aluminum adjuvant, calculated as aluminum ions, is 0.1–1.0 mg / mL.

15. The vaccine according to claim 14, characterized in that, The final concentration of aluminum in the aluminum adjuvant, calculated as aluminum ions, is 0.2–0.8 mg / mL.

16. The use of the vaccine according to any one of claims 1 to 15 in the preparation of a medicament for the prevention of hand-foot-mouth disease.

Citation Information

Patent Citations

  • Combined vaccine for preventing hand-foot-and-mouth disease

    CN106075423A

  • Construction method of recombinant enterovirus phenotype hybrid system and application

    CN106636001A

  • Viral particles as immunogens against enterovirus infection and production thereof

    CN106661102A

  • Combined vaccine for preventing hand-foot-and-mouth disease as well as preparation method and application thereof

    CN112717128A

  • Combined vaccine for preventing hand-foot-and-mouth disease as well as preparation method and application thereof

    CN112791179A